SCHEMBL28537816

SCHEMBL28537816

Cn1nccc1-c1ncc(C(=O)NC(CN)Cc2cccc(F)c2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 7/20 0.58
AKT2 P31751 6/20 0.58
AKT3 Q9Y243 6/20 0.58
ROCK1 Q13464 4/20 0.58
PRKCA P17252 3/20 0.58
ROCK2 O75116 2/20 0.58
PRKCB P05771 2/20 0.58
PRKACA P17612 2/20 0.58
PRKACB P22694 2/20 0.58
PKN1 Q16512 2/20 0.58
PRKD2 Q9BZL6 2/20 0.58
CIT O14578 1/20 0.58
EGFR P00533 1/20 0.48
PIM1 P11309 1/20 0.48
SYK P43405 1/20 0.48
MAPKAPK2 P49137 1/20 0.48
GSK3B P49841 1/20 0.48
MAPK14 Q16539 1/20 0.48
PIN1 Q13526 3/20 0.44
SGK1 O00141 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1591842 1.00 AKT1 (0.58) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL1539458 0.87 AKT1 (0.47) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL28534564 0.86 AKT1 (0.57) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL1641583 0.86 AKT1 (0.57) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL1591685 0.84 AKT1 (0.76) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL28526551 0.84 AKT1 (0.76) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL1529491 0.84 AKT1 (0.63) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL1529390 0.83 AKT1 (0.74) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL13509109 0.83 AKT1 (0.74) AKT1AKT2AKT3ROCK1PRKCA
SCHEMBL676006 0.83 AKT1 (0.51) AKT1AKT2AKT3ROCK1PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113365610-A Methods of making and delivering bisantrene formulations 现代化制药公司 2021-09-07 CN disclosed
CN-112472699-A Combination methods for improving the therapeutic benefit of bisantrene and derivatives 种族肿瘤学公司 2021-03-12 CN disclosed